Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

NCT03232567 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT03232567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03232567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Lead sponsor
Altimmune, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2017
Completion date
June 15, 2018
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza